NCT05937581View on ClinicalTrials.gov

First-In-Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Escalating Single And Multiple Doses Of CSL040 In Healthy Subjects

PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 28, 2023

Primary Completion Date

December 11, 2025

Study Completion Date

December 11, 2025

Conditions
Complement-mediated Disorders
Interventions
DRUG

CSL040

IV Administration

DRUG

Placebo

0.9% w/v NaCI, IV Administration

Trial Locations (1)

4006

RECRUITING

Nucleus Network Pty Ltd, Herston

Sponsors

Lead Sponsor

CSL Behring
All Listed Sponsors
lead

CSL Behring

INDUSTRY